The same molecule, two regulatory worlds

Every row cites its source. Where a cell reflects our own reading of the evidence rather than an external source, the row says so.

Compounded, not FDA-approved

Semax is not FDA approved for any use in the U.S. It is sold as a research chemical; FDA has proposed not to allow it in compounded drugs, and efficacy has not been established to FDA standards.

RESEARCH-ONLY in the United States. No FDA-approved product contains semax; a Drugs@FDA query for it as an active ingredient returns no matches. FDA lists Semax (heptapeptide) on its page of bulk drug substances that may present significant safety risks in compounding, and at the July 23 to 24, 2026 Pharmacy Compounding Advisory Committee meeting FDA proposed that both Semax (free base) and Semax acetate NOT be included on the 503A Bulks List. Peer-reviewed literature describes semax as a Russian clinical drug; this site could not verify a Russian marketing authorisation against the state register and therefore does not assert one.

The same molecule, two regulatory worlds
Question	As described in the Russian-facing literature	In the United States	Source
Regulatory standing	A 2022 peer-reviewed review states 14 peptide products are registered in the Russian Federation and lists semax among them. This site could not verify the registration against the state register itself	Not approved for any use. A Drugs@FDA query for semax as an active ingredient returns no matches	source
Clinical role	The same review states semax "is used to treat ischemic stroke due to its nootropic, neuroprotective, and immunomodulatory effects"	No clinical role. It is sold as a research chemical with no approved indication	source
Who made it	Synthesized at the Institute of Molecular Genetics of the Russian Academy of Sciences under academicians Ashmarin and Myasoedov	No US developer, no US development programme, and zero studies registered on ClinicalTrials.gov	source
Compounding pharmacy access	Not applicable; the product route described is a registered medicine	FDA proposed in July 2026 that semax not be added to the 503A Bulks List, and listing would not equal approval in any case	source
Quality standard behind what a buyer receives	A registered product carries its manufacturer's standard	None. No approved product means no product-level standard; FDA cites aggregation and peptide-related impurities as immunogenicity risks	source
How the evidence reads to an outside analyst	Decades of clinical reports, mostly in Russian, mostly non-randomized	A Belgian government laboratory wrote in 2020 that semax and selank "have not completed any clinical trials", a statement made twelve years after Russian clinical reports were being indexed	source

This table is the honest form of a claim vendors make carelessly. The left column is what peer-reviewed sources say about semax in Russia; it is not a registration record, because this site could not query the Russian state register. The right column is checkable against FDA sources directly.